| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Abdominal Injuries | 10 | 2022 | 60 | 4.690 |
Why?
|
| Wounds, Nonpenetrating | 10 | 2022 | 131 | 4.300 |
Why?
|
| Neuroblastoma | 9 | 2008 | 109 | 1.560 |
Why?
|
| Unnecessary Procedures | 3 | 2017 | 49 | 1.380 |
Why?
|
| Tomography, X-Ray Computed | 11 | 2018 | 2324 | 1.370 |
Why?
|
| Herniorrhaphy | 4 | 2020 | 38 | 1.150 |
Why?
|
| Trauma Centers | 8 | 2022 | 197 | 1.120 |
Why?
|
| Decision Support Techniques | 3 | 2018 | 191 | 1.080 |
Why?
|
| Appendicitis | 4 | 2014 | 55 | 1.040 |
Why?
|
| Child | 28 | 2022 | 6405 | 0.950 |
Why?
|
| Child, Preschool | 19 | 2022 | 3187 | 0.950 |
Why?
|
| Practice Guidelines as Topic | 3 | 2020 | 772 | 0.920 |
Why?
|
| Injury Severity Score | 9 | 2022 | 204 | 0.850 |
Why?
|
| Quality Improvement | 4 | 2021 | 413 | 0.840 |
Why?
|
| Clinical Clerkship | 1 | 2022 | 63 | 0.800 |
Why?
|
| Wounds and Injuries | 5 | 2020 | 334 | 0.790 |
Why?
|
| Thoracic Injuries | 2 | 2012 | 44 | 0.780 |
Why?
|
| Angiogenesis Inhibitors | 4 | 2006 | 64 | 0.780 |
Why?
|
| Neovascularization, Pathologic | 7 | 2007 | 183 | 0.750 |
Why?
|
| Interferon-beta | 5 | 2010 | 17 | 0.740 |
Why?
|
| Teratoma | 2 | 2010 | 22 | 0.720 |
Why?
|
| Patient Discharge | 3 | 2022 | 294 | 0.710 |
Why?
|
| Adolescent | 21 | 2021 | 8912 | 0.700 |
Why?
|
| Students, Medical | 1 | 2022 | 210 | 0.700 |
Why?
|
| Internship and Residency | 3 | 2022 | 596 | 0.700 |
Why?
|
| Duodenal Diseases | 1 | 2018 | 15 | 0.640 |
Why?
|
| Venous Thromboembolism | 3 | 2017 | 117 | 0.640 |
Why?
|
| Hernia | 1 | 2018 | 13 | 0.640 |
Why?
|
| Intestinal Obstruction | 1 | 2018 | 36 | 0.630 |
Why?
|
| Genetic Therapy | 6 | 2006 | 291 | 0.620 |
Why?
|
| Ultrasonography | 3 | 2017 | 453 | 0.620 |
Why?
|
| Intestine, Small | 1 | 2018 | 89 | 0.610 |
Why?
|
| Dependovirus | 7 | 2010 | 34 | 0.550 |
Why?
|
| Appendectomy | 3 | 2013 | 47 | 0.550 |
Why?
|
| Humans | 52 | 2022 | 68618 | 0.540 |
Why?
|
| Laparoscopy | 5 | 2020 | 237 | 0.540 |
Why?
|
| Prospective Studies | 9 | 2022 | 3705 | 0.510 |
Why?
|
| Risk Assessment | 9 | 2020 | 2007 | 0.510 |
Why?
|
| Male | 31 | 2022 | 37321 | 0.490 |
Why?
|
| Emergency Medical Services | 1 | 2017 | 225 | 0.490 |
Why?
|
| Emergency Service, Hospital | 1 | 2020 | 711 | 0.480 |
Why?
|
| Famous Persons | 1 | 2014 | 15 | 0.460 |
Why?
|
| Intermittent Pneumatic Compression Devices | 1 | 2013 | 6 | 0.450 |
Why?
|
| Abdomen, Acute | 1 | 2013 | 14 | 0.440 |
Why?
|
| Critical Pathways | 1 | 2013 | 33 | 0.440 |
Why?
|
| Genetic Vectors | 4 | 2006 | 312 | 0.420 |
Why?
|
| Desmoplastic Small Round Cell Tumor | 1 | 2012 | 3 | 0.420 |
Why?
|
| Sensitivity and Specificity | 6 | 2018 | 1753 | 0.410 |
Why?
|
| Peritoneal Neoplasms | 1 | 2012 | 23 | 0.410 |
Why?
|
| Thoracic Surgery, Video-Assisted | 1 | 2011 | 19 | 0.390 |
Why?
|
| Infant | 10 | 2021 | 2891 | 0.370 |
Why?
|
| Retrospective Studies | 13 | 2022 | 7277 | 0.370 |
Why?
|
| Guideline Adherence | 1 | 2013 | 287 | 0.370 |
Why?
|
| Female | 24 | 2022 | 38074 | 0.370 |
Why?
|
| Autoimmune Diseases of the Nervous System | 1 | 2010 | 3 | 0.370 |
Why?
|
| Paraneoplastic Syndromes, Nervous System | 1 | 2010 | 5 | 0.370 |
Why?
|
| Mediastinal Neoplasms | 1 | 2010 | 27 | 0.360 |
Why?
|
| Encephalitis | 1 | 2010 | 43 | 0.360 |
Why?
|
| Liver Neoplasms | 2 | 2004 | 334 | 0.350 |
Why?
|
| Catheterization, Central Venous | 3 | 2016 | 89 | 0.350 |
Why?
|
| Fibrinolytic Agents | 1 | 2013 | 377 | 0.350 |
Why?
|
| Lung Diseases | 1 | 2011 | 175 | 0.340 |
Why?
|
| Length of Stay | 4 | 2020 | 780 | 0.330 |
Why?
|
| Vascular Endothelial Growth Factor Receptor-2 | 3 | 2006 | 32 | 0.320 |
Why?
|
| Retroperitoneal Neoplasms | 2 | 2006 | 12 | 0.320 |
Why?
|
| Ovarian Neoplasms | 1 | 2010 | 267 | 0.320 |
Why?
|
| Receptors, N-Methyl-D-Aspartate | 1 | 2010 | 266 | 0.310 |
Why?
|
| Hernia, Inguinal | 2 | 2020 | 21 | 0.300 |
Why?
|
| Pediatrics | 3 | 2017 | 341 | 0.290 |
Why?
|
| Hospitals, Pediatric | 4 | 2017 | 114 | 0.290 |
Why?
|
| Xenograft Model Antitumor Assays | 3 | 2010 | 304 | 0.270 |
Why?
|
| Interferon Type I | 2 | 2006 | 32 | 0.270 |
Why?
|
| Laparotomy | 3 | 2017 | 65 | 0.270 |
Why?
|
| Intestines | 1 | 2006 | 114 | 0.270 |
Why?
|
| Interferons | 1 | 2005 | 36 | 0.260 |
Why?
|
| Interferon-alpha | 2 | 2006 | 46 | 0.250 |
Why?
|
| Neoplasm Transplantation | 5 | 2007 | 160 | 0.250 |
Why?
|
| Cyclophosphamide | 1 | 2005 | 129 | 0.250 |
Why?
|
| Ultrasonography, Interventional | 2 | 2016 | 119 | 0.250 |
Why?
|
| Angiography | 3 | 2021 | 194 | 0.240 |
Why?
|
| Antineoplastic Agents | 4 | 2010 | 1070 | 0.240 |
Why?
|
| Nerve Growth Factors | 1 | 2005 | 75 | 0.240 |
Why?
|
| Endostatins | 1 | 2004 | 11 | 0.230 |
Why?
|
| Infant, Newborn | 5 | 2020 | 2455 | 0.230 |
Why?
|
| Eye Proteins | 1 | 2005 | 160 | 0.230 |
Why?
|
| Neoplasms, Second Primary | 1 | 2004 | 62 | 0.220 |
Why?
|
| Gene Transfer Techniques | 1 | 2004 | 173 | 0.220 |
Why?
|
| Cell Line, Tumor | 8 | 2010 | 1851 | 0.220 |
Why?
|
| Diagnosis, Differential | 3 | 2018 | 1140 | 0.220 |
Why?
|
| Follow-Up Studies | 6 | 2020 | 3259 | 0.220 |
Why?
|
| Serpins | 1 | 2005 | 205 | 0.210 |
Why?
|
| Mice, SCID | 5 | 2010 | 238 | 0.210 |
Why?
|
| Digestive System Abnormalities | 1 | 2022 | 7 | 0.200 |
Why?
|
| Mice | 11 | 2010 | 8474 | 0.200 |
Why?
|
| Esophageal Diseases | 1 | 2022 | 95 | 0.200 |
Why?
|
| Sentinel Lymph Node Biopsy | 2 | 2012 | 53 | 0.190 |
Why?
|
| Caregivers | 2 | 2022 | 365 | 0.190 |
Why?
|
| Aftercare | 1 | 2022 | 114 | 0.190 |
Why?
|
| Schools, Medical | 1 | 2022 | 157 | 0.190 |
Why?
|
| Patient Admission | 1 | 2021 | 99 | 0.190 |
Why?
|
| Observational Studies as Topic | 1 | 2020 | 39 | 0.190 |
Why?
|
| Blood Component Transfusion | 1 | 2020 | 11 | 0.180 |
Why?
|
| Educational Measurement | 1 | 2022 | 254 | 0.180 |
Why?
|
| Diagnostic Errors | 2 | 2013 | 100 | 0.180 |
Why?
|
| Emergency Treatment | 1 | 2020 | 52 | 0.180 |
Why?
|
| Stress Disorders, Post-Traumatic | 2 | 2022 | 1506 | 0.180 |
Why?
|
| Multicenter Studies as Topic | 1 | 2020 | 186 | 0.180 |
Why?
|
| Polycystic Kidney, Autosomal Dominant | 1 | 2020 | 25 | 0.180 |
Why?
|
| Workplace | 1 | 2020 | 75 | 0.180 |
Why?
|
| Hematoma | 1 | 2020 | 47 | 0.180 |
Why?
|
| Resuscitation | 1 | 2020 | 77 | 0.170 |
Why?
|
| False Negative Reactions | 2 | 2017 | 63 | 0.170 |
Why?
|
| Skin Neoplasms | 1 | 2004 | 375 | 0.170 |
Why?
|
| Burnout, Professional | 1 | 2020 | 64 | 0.170 |
Why?
|
| Time-to-Treatment | 1 | 2020 | 117 | 0.170 |
Why?
|
| Treatment Outcome | 7 | 2020 | 7029 | 0.170 |
Why?
|
| Resilience, Psychological | 1 | 2019 | 43 | 0.170 |
Why?
|
| Combined Modality Therapy | 3 | 2013 | 951 | 0.160 |
Why?
|
| Subclavian Vein | 2 | 2016 | 17 | 0.160 |
Why?
|
| Postoperative Complications | 2 | 2017 | 1615 | 0.160 |
Why?
|
| Accidents, Traffic | 1 | 2019 | 109 | 0.160 |
Why?
|
| United States | 5 | 2022 | 7367 | 0.150 |
Why?
|
| Mental Health | 1 | 2019 | 278 | 0.140 |
Why?
|
| Specialties, Surgical | 1 | 2017 | 19 | 0.140 |
Why?
|
| Physicians | 1 | 2020 | 324 | 0.140 |
Why?
|
| Health Promotion | 1 | 2020 | 407 | 0.140 |
Why?
|
| Surgical Wound Infection | 2 | 2015 | 168 | 0.140 |
Why?
|
| Transplantation, Heterologous | 3 | 2006 | 122 | 0.140 |
Why?
|
| Animals | 11 | 2010 | 20881 | 0.140 |
Why?
|
| Surgical Wound | 1 | 2015 | 8 | 0.130 |
Why?
|
| Reproducibility of Results | 2 | 2018 | 2077 | 0.130 |
Why?
|
| Embolization, Therapeutic | 1 | 2017 | 150 | 0.130 |
Why?
|
| Age Factors | 3 | 2017 | 1864 | 0.130 |
Why?
|
| Kidney | 1 | 2020 | 945 | 0.130 |
Why?
|
| Intraoperative Care | 1 | 2015 | 91 | 0.130 |
Why?
|
| Consensus | 1 | 2016 | 211 | 0.130 |
Why?
|
| Survival Analysis | 3 | 2008 | 714 | 0.130 |
Why?
|
| Central Venous Catheters | 1 | 2015 | 19 | 0.120 |
Why?
|
| Jugular Veins | 1 | 2015 | 37 | 0.120 |
Why?
|
| Logistic Models | 2 | 2017 | 1420 | 0.120 |
Why?
|
| Orthopedic Procedures | 1 | 2016 | 102 | 0.120 |
Why?
|
| Benchmarking | 1 | 2014 | 91 | 0.120 |
Why?
|
| History, 15th Century | 1 | 2014 | 6 | 0.120 |
Why?
|
| History, Medieval | 1 | 2014 | 8 | 0.120 |
Why?
|
| History, 16th Century | 1 | 2014 | 8 | 0.120 |
Why?
|
| History, 17th Century | 1 | 2014 | 17 | 0.120 |
Why?
|
| History, 18th Century | 1 | 2014 | 26 | 0.120 |
Why?
|
| History, Ancient | 1 | 2014 | 25 | 0.120 |
Why?
|
| Neoplasm Metastasis | 2 | 2006 | 306 | 0.120 |
Why?
|
| History, 19th Century | 1 | 2014 | 95 | 0.110 |
Why?
|
| Quality Indicators, Health Care | 1 | 2014 | 136 | 0.110 |
Why?
|
| Surgical Procedures, Operative | 1 | 2014 | 124 | 0.110 |
Why?
|
| Vascular Endothelial Growth Factor A | 2 | 2005 | 219 | 0.110 |
Why?
|
| Cohort Studies | 3 | 2020 | 2358 | 0.110 |
Why?
|
| Hospitals, Urban | 1 | 2013 | 46 | 0.110 |
Why?
|
| Delayed Diagnosis | 1 | 2013 | 39 | 0.110 |
Why?
|
| History, 20th Century | 1 | 2014 | 248 | 0.110 |
Why?
|
| Tertiary Care Centers | 1 | 2013 | 67 | 0.110 |
Why?
|
| Incidence | 2 | 2017 | 1603 | 0.110 |
Why?
|
| Depression | 1 | 2019 | 943 | 0.100 |
Why?
|
| Omentum | 1 | 2012 | 18 | 0.100 |
Why?
|
| Substance-Related Disorders | 1 | 2022 | 1242 | 0.100 |
Why?
|
| Multiple Trauma | 1 | 2012 | 50 | 0.100 |
Why?
|
| Prognosis | 1 | 2017 | 2093 | 0.100 |
Why?
|
| Emergency Medicine | 1 | 2013 | 88 | 0.100 |
Why?
|
| Confidence Intervals | 1 | 2012 | 242 | 0.100 |
Why?
|
| Education, Medical, Continuing | 1 | 2013 | 136 | 0.100 |
Why?
|
| Cost Savings | 1 | 2012 | 110 | 0.100 |
Why?
|
| Occlusive Dressings | 1 | 2011 | 7 | 0.100 |
Why?
|
| Sarcoma | 1 | 2012 | 70 | 0.100 |
Why?
|
| Clinical Competence | 1 | 2017 | 657 | 0.100 |
Why?
|
| Radiation Injuries | 1 | 2012 | 97 | 0.100 |
Why?
|
| beta-Glucans | 1 | 2011 | 18 | 0.100 |
Why?
|
| Immunohistochemistry | 4 | 2010 | 1174 | 0.100 |
Why?
|
| Pylorus | 1 | 2011 | 6 | 0.100 |
Why?
|
| Coated Materials, Biocompatible | 1 | 2011 | 54 | 0.100 |
Why?
|
| Nucleic Acid Amplification Techniques | 1 | 2011 | 21 | 0.090 |
Why?
|
| Patient Care Team | 1 | 2013 | 311 | 0.090 |
Why?
|
| Lymph Nodes | 1 | 2012 | 258 | 0.090 |
Why?
|
| Neoplasm Staging | 2 | 2010 | 800 | 0.090 |
Why?
|
| Abdominal Abscess | 1 | 2010 | 8 | 0.090 |
Why?
|
| Sternotomy | 1 | 2010 | 18 | 0.090 |
Why?
|
| Thoracotomy | 1 | 2010 | 25 | 0.090 |
Why?
|
| Abdominal Wall | 1 | 2010 | 20 | 0.090 |
Why?
|
| Myeloid-Lymphoid Leukemia Protein | 1 | 2010 | 8 | 0.090 |
Why?
|
| Burns | 1 | 2011 | 83 | 0.090 |
Why?
|
| Gene Rearrangement | 1 | 2010 | 19 | 0.090 |
Why?
|
| Gene Expression Regulation, Leukemic | 1 | 2010 | 29 | 0.090 |
Why?
|
| Odds Ratio | 1 | 2012 | 880 | 0.090 |
Why?
|
| Eosinophilia | 1 | 2010 | 47 | 0.090 |
Why?
|
| Cough | 1 | 2010 | 65 | 0.090 |
Why?
|
| Apoptosis | 3 | 2010 | 1641 | 0.090 |
Why?
|
| Radiography, Thoracic | 1 | 2010 | 99 | 0.090 |
Why?
|
| Precursor Cell Lymphoblastic Leukemia-Lymphoma | 1 | 2010 | 70 | 0.080 |
Why?
|
| Intensive Care Units | 2 | 2022 | 344 | 0.080 |
Why?
|
| Disease Models, Animal | 3 | 2006 | 2550 | 0.080 |
Why?
|
| Predictive Value of Tests | 1 | 2012 | 1465 | 0.080 |
Why?
|
| Wilms Tumor | 1 | 2008 | 47 | 0.080 |
Why?
|
| Collagen | 1 | 2011 | 636 | 0.080 |
Why?
|
| NF-kappa B | 1 | 2010 | 432 | 0.080 |
Why?
|
| Leukemia, Myeloid | 1 | 2006 | 39 | 0.070 |
Why?
|
| Kidney Neoplasms | 1 | 2008 | 206 | 0.070 |
Why?
|
| Risk Factors | 2 | 2014 | 5731 | 0.070 |
Why?
|
| Disease Progression | 1 | 2010 | 1038 | 0.070 |
Why?
|
| Albumins | 1 | 2006 | 72 | 0.070 |
Why?
|
| Fluorocarbons | 1 | 2006 | 82 | 0.060 |
Why?
|
| Remission Induction | 1 | 2005 | 111 | 0.060 |
Why?
|
| Antineoplastic Agents, Alkylating | 1 | 2005 | 57 | 0.060 |
Why?
|
| Models, Genetic | 1 | 2006 | 161 | 0.060 |
Why?
|
| Cell Proliferation | 2 | 2010 | 1174 | 0.060 |
Why?
|
| Abdominal Pain | 2 | 2020 | 97 | 0.060 |
Why?
|
| Recurrence | 2 | 2020 | 948 | 0.060 |
Why?
|
| Dose-Response Relationship, Drug | 2 | 2006 | 1745 | 0.060 |
Why?
|
| Carcinoma, Renal Cell | 1 | 2006 | 110 | 0.060 |
Why?
|
| Hospitalization | 2 | 2022 | 978 | 0.060 |
Why?
|
| Mice, Inbred Strains | 1 | 2005 | 181 | 0.060 |
Why?
|
| Protease Inhibitors | 1 | 2005 | 76 | 0.060 |
Why?
|
| In Situ Nick-End Labeling | 1 | 2004 | 160 | 0.060 |
Why?
|
| Recombinant Proteins | 1 | 2005 | 742 | 0.060 |
Why?
|
| Cell Division | 1 | 2004 | 541 | 0.060 |
Why?
|
| Algorithms | 3 | 2015 | 1196 | 0.060 |
Why?
|
| Models, Animal | 1 | 2004 | 252 | 0.050 |
Why?
|
| Glioblastoma | 1 | 2006 | 219 | 0.050 |
Why?
|
| Contrast Media | 1 | 2006 | 595 | 0.050 |
Why?
|
| Cell Survival | 1 | 2005 | 901 | 0.050 |
Why?
|
| Child Health | 1 | 2022 | 15 | 0.050 |
Why?
|
| Incidental Findings | 1 | 2022 | 42 | 0.050 |
Why?
|
| Analysis of Variance | 1 | 2004 | 1040 | 0.050 |
Why?
|
| Magnetic Resonance Imaging | 1 | 2010 | 2223 | 0.050 |
Why?
|
| Breast Neoplasms | 1 | 2011 | 1536 | 0.050 |
Why?
|
| Lymphatic Metastasis | 2 | 2012 | 274 | 0.050 |
Why?
|
| Qualitative Research | 1 | 2022 | 369 | 0.050 |
Why?
|
| Emotions | 1 | 2022 | 244 | 0.050 |
Why?
|
| Cell Differentiation | 1 | 2005 | 1034 | 0.050 |
Why?
|
| Basketball | 1 | 2020 | 3 | 0.050 |
Why?
|
| Lacerations | 1 | 2020 | 13 | 0.040 |
Why?
|
| Monitoring, Physiologic | 1 | 2021 | 219 | 0.040 |
Why?
|
| Hematuria | 1 | 2020 | 24 | 0.040 |
Why?
|
| Cell Line | 1 | 2004 | 1752 | 0.040 |
Why?
|
| General Surgery | 1 | 2020 | 95 | 0.040 |
Why?
|
| Perception | 1 | 2020 | 189 | 0.040 |
Why?
|
| Neurons | 1 | 2005 | 881 | 0.040 |
Why?
|
| Biopsy, Needle | 2 | 2010 | 191 | 0.040 |
Why?
|
| Blood Transfusion | 1 | 2020 | 205 | 0.040 |
Why?
|
| Infant, Premature | 1 | 2020 | 284 | 0.040 |
Why?
|
| Hospital Mortality | 1 | 2020 | 384 | 0.040 |
Why?
|
| Registries | 1 | 2021 | 733 | 0.040 |
Why?
|
| Child, Hospitalized | 1 | 2017 | 16 | 0.040 |
Why?
|
| Antihypertensive Agents | 1 | 2020 | 498 | 0.030 |
Why?
|
| Neoplasms | 1 | 2007 | 1667 | 0.030 |
Why?
|
| Mass Screening | 1 | 2022 | 843 | 0.030 |
Why?
|
| Academic Medical Centers | 1 | 2017 | 281 | 0.030 |
Why?
|
| Needles | 1 | 2014 | 34 | 0.030 |
Why?
|
| Operative Time | 1 | 2014 | 45 | 0.030 |
Why?
|
| Chi-Square Distribution | 1 | 2015 | 546 | 0.030 |
Why?
|
| Sarcoma, Clear Cell | 1 | 2012 | 8 | 0.030 |
Why?
|
| Sarcoma, Synovial | 1 | 2012 | 11 | 0.030 |
Why?
|
| Patient Selection | 1 | 2016 | 592 | 0.030 |
Why?
|
| Longitudinal Studies | 1 | 2015 | 1054 | 0.030 |
Why?
|
| Rhabdomyosarcoma | 1 | 2012 | 36 | 0.030 |
Why?
|
| Monte Carlo Method | 1 | 2012 | 124 | 0.020 |
Why?
|
| Practice Patterns, Physicians' | 1 | 2016 | 504 | 0.020 |
Why?
|
| Markov Chains | 1 | 2012 | 133 | 0.020 |
Why?
|
| Polyhydramnios | 1 | 2011 | 2 | 0.020 |
Why?
|
| Digestive System Surgical Procedures | 1 | 2011 | 30 | 0.020 |
Why?
|
| Electronic Health Records | 1 | 2014 | 374 | 0.020 |
Why?
|
| Rare Diseases | 1 | 2010 | 41 | 0.020 |
Why?
|
| Bayes Theorem | 1 | 2012 | 307 | 0.020 |
Why?
|
| Chromosomes, Human, Pair 4 | 1 | 2010 | 15 | 0.020 |
Why?
|
| Chromosomes, Human, Pair 11 | 1 | 2010 | 32 | 0.020 |
Why?
|
| Electrophoretic Mobility Shift Assay | 1 | 2010 | 60 | 0.020 |
Why?
|
| Translocation, Genetic | 1 | 2010 | 74 | 0.020 |
Why?
|
| JNK Mitogen-Activated Protein Kinases | 1 | 2010 | 140 | 0.020 |
Why?
|
| Wound Healing | 1 | 2011 | 260 | 0.020 |
Why?
|
| Young Adult | 1 | 2020 | 5717 | 0.020 |
Why?
|
| Flow Cytometry | 1 | 2010 | 489 | 0.020 |
Why?
|
| Adaptor Proteins, Signal Transducing | 1 | 2010 | 214 | 0.020 |
Why?
|
| Tumor Cells, Cultured | 1 | 2010 | 852 | 0.020 |
Why?
|
| Reverse Transcriptase Polymerase Chain Reaction | 1 | 2010 | 710 | 0.020 |
Why?
|
| Chemotherapy, Adjuvant | 1 | 2008 | 129 | 0.020 |
Why?
|
| Nephrectomy | 1 | 2008 | 103 | 0.020 |
Why?
|
| Blotting, Western | 1 | 2010 | 954 | 0.020 |
Why?
|
| Drug Resistance, Neoplasm | 1 | 2010 | 332 | 0.020 |
Why?
|
| Angiopoietin-1 | 1 | 2007 | 12 | 0.020 |
Why?
|
| Disease-Free Survival | 1 | 2008 | 349 | 0.020 |
Why?
|
| Recovery of Function | 1 | 2011 | 506 | 0.020 |
Why?
|
| Drug Administration Routes | 1 | 2006 | 25 | 0.020 |
Why?
|
| Surveys and Questionnaires | 1 | 2015 | 2800 | 0.020 |
Why?
|
| Ultrasonography, Doppler, Color | 1 | 2006 | 21 | 0.020 |
Why?
|
| Microspheres | 1 | 2006 | 59 | 0.020 |
Why?
|
| Tissue Inhibitor of Metalloproteinase-3 | 1 | 2006 | 15 | 0.020 |
Why?
|
| Mice, Inbred CBA | 1 | 2006 | 107 | 0.020 |
Why?
|
| Tumor Burden | 1 | 2006 | 132 | 0.020 |
Why?
|
| Preoperative Care | 1 | 2008 | 275 | 0.020 |
Why?
|
| Drug Evaluation, Preclinical | 1 | 2006 | 137 | 0.020 |
Why?
|
| Hypoxia | 1 | 2007 | 169 | 0.020 |
Why?
|
| Multivariate Analysis | 1 | 2009 | 1046 | 0.020 |
Why?
|
| Adenoviridae | 1 | 2006 | 295 | 0.020 |
Why?
|
| RNA, Messenger | 1 | 2010 | 1664 | 0.020 |
Why?
|
| Pregnancy | 1 | 2011 | 2334 | 0.020 |
Why?
|
| Biological Availability | 1 | 2005 | 79 | 0.020 |
Why?
|
| Solubility | 1 | 2005 | 134 | 0.020 |
Why?
|
| Acute Disease | 1 | 2006 | 658 | 0.020 |
Why?
|
| Transfection | 1 | 2006 | 782 | 0.020 |
Why?
|
| Ligands | 1 | 2005 | 317 | 0.010 |
Why?
|
| Cytokines | 1 | 2007 | 866 | 0.010 |
Why?
|
| Image Processing, Computer-Assisted | 1 | 2006 | 689 | 0.010 |
Why?
|
| Time Factors | 1 | 2011 | 4655 | 0.010 |
Why?
|
| Gene Expression | 1 | 2005 | 770 | 0.010 |
Why?
|
| Anti-Bacterial Agents | 1 | 2009 | 1026 | 0.010 |
Why?
|
| Aged, 80 and over | 1 | 2011 | 4848 | 0.010 |
Why?
|
| Aged | 1 | 2011 | 14862 | 0.010 |
Why?
|
| Middle Aged | 1 | 2011 | 21147 | 0.010 |
Why?
|
| Adult | 1 | 2011 | 21403 | 0.010 |
Why?
|